急性早幼粒细胞白血病成功治疗后继发治疗相关性髓系肿瘤:四例报告及文献复习
该研究回顾性分析4例APL成功治疗后继发t-MN患者的临床资料并复习文献。4例均为女性,中位年龄42岁,APL完全缓解后40~43个月出现t-MN,其中t-MDS 1例、t-AML 3例。中位随访54.5个月,2例t-AML死亡,t-MN后中位生存期12个月。文献汇总67例,中位潜伏期39个月,确诊t-MN后中位生存10个月。
要点
- APL成功治疗后40~43个月可能继发t-MN,以t-AML多见。
- 出现t-MN时PML-RARα融合基因均为阴性。
- t-MN预后差,确诊后中位生存约10~12个月。
核心结论
- APL继发t-MN较为少见,目前缺乏有效防治措施,预后不佳。
- APL获得CR后39个月左右若出现病情变化,应警惕t-MN。
研究设计与样本
- 回顾性分析中国医学科学院血液病医院2012年10月至2019年1月收治的4例APL继发t-MN患者,并复习相关文献。
- 文献汇总1989至2018年报道的63例APL继发t-MN病例,与本中心4例合计67例进行分析。
主要发现
- 本中心4例均为女性,诊断APL时中位年龄42(40~53)岁,APL完全缓解后40~43个月出现t-MN,其中t-MDS 1例、t-AML 3例。
- 4例出现t-MN时PML-RARα融合基因均为阴性。
- 本中心中位随访54.5(48~62)个月,2例t-AML患者死亡,出现t-MN后中位生存期为12(5~18)个月。
- 汇总67例中男27例、女40例,中位年龄52.5(15~76)岁,中位潜伏期39(12~126)个月,确诊t-MN后中位生存时间10(1~39)个月。
关键数值与推荐
- 3例t-AML患者接受了3~4个再诱导 regimens,其中1例获CR后行allo-HSCT。
- 1例t-MDS患者接受了去甲基化治疗。
临床怎么用
- APL成功治疗后随访中,尤其CR后3年左右,若出现血细胞减少或其他外周血细胞异常,应鉴别t-MN。
- 对疑似t-MN患者应尽快明确疾病变化并给予合理治疗。
局限性
- 本中心部分为回顾性小样本(4例)分析。
- 文献汇总数据来自1989至2018年报道,可能存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical characteristics, diagnosis, treatment and prognosis of therapy-related myeloid neoplasms (t-MNs) after successful treatment for acute promyelocytic leukemia (APL) . Methods: Clinical data of 4 patients, diagnosed as t-MNs secondary to APL at Hematology Hospital of Chinese Academy of Medical Sciences from October 2012 to January 2019, were collected retrospectively. T-MNs related literature was reviewed. Results: The 4 cases were all females, with the median age 42 (range 40-53) years old at the diagnosis of APL. Regarding the induction and consolidation regimens, 3 patients received all-trans retinoid acid (ATRA) and arsenic trioxide (ATO) combined with anthracycline/anthraquinone and/or cytosine. One patient only received ATRA and other auxiliary drugs. Alkylating agents were not administrated. The 4 patients developed t-MNs 40 to 43 months after complete remission (CR) of APL, including 1 case of therapy-related myelodysplastic syndrome (t-MDS) and 3 cases of acute myeloid leukemia (t-AML) . The PML-RARα fusion genes were all negative when t-MNs developed. The three patients with t-AML were treated with 3 to 4 re-induction regimens, one of whom underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) after complete remission (CR) . One patient with t-MDS received hypomethylating agents. After a median follow-up of 54.5 (48-62) months, 2 patients with t-AML died, the median overall survival after t-MN was 12 (5-18) months. From 1989 to 2018, a total of 63 t-MN cases were reported in the literature. Therefore, 67 cases were analyzed when four patients in our center were added, including 27 males and 40 females with median age 52.5 (15-76) years. The median latency was 39 (12-126) months and the median overall survival after diagnosis of t-MN was 10 (1-39) months. Conclusions: Although rare, t-MNs may occur after successful control of APL. There are no existing guidelines for prevention and treatment of t-MNs, which have very poor prognosis. If cytopenia or other abnormalities of peripheral blood cells develop after 3 years of APL, t-MNs should be considered as a differential diagnosis. 目的: 探讨急性早幼粒细胞白血病(APL)患者继发治疗相关性髓系肿瘤(t-MN)的临床特点、诊断、治疗及预后。 方法: 回顾性分析中国医学科学院血液病医院2012年10月至2019年1月收治的4例APL继发t-MN患者的临床资料,并进行相关文献复习。 结果: 4例APL继发t-MN患者均为女性,中位年龄42(40~53)岁,3例接受了以维甲酸(ATRA)+亚砷酸(ATO)为基础联合蒽环/蒽醌类药物±阿糖胞苷的前期诱导缓解及巩固治疗方案,1例采用了ATRA联合蒽环/蒽醌类药物±阿糖胞苷的治疗方案,均没有使用烷化剂。在APL获得完全缓解(CR)后40~43个月出现t-MN,其中治疗相关性骨髓增生异常综合征(t-MDS)1例,治疗相关性急性髓系白血病(t-AML)3例,出现t-MN时PML-RARα融合基因均为阴性。3例t-AML患者接受了2~4个疗程再诱导治疗,其中有1例t-AML患者在获得CR后行异基因造血干细胞移植(allo-HSCT),1例t-MDS患者接受了去甲基化治疗。中位随访54.5(48~62)个月,2例t-AML患者死亡,出现t-MN后中位生存期为12(5~18)个月。1989至2018年文献共报道63例APL继发t-MN病例,与本次报道的4例汇总分析,67例患者中男27例,女40例;中位年龄为52.5(15~76)岁;中位潜伏期39(12~168)个月,确诊t-MN后中位生存时间为10(1~39)个月。 结论: APL继发t-MN较为少见,目前缺乏有效的防治措施,预后不佳,在随访过程中(尤其是获得CR后39个月左右)若出现病情变化,应警惕t-MN的发生,对此类患者应尽快明确疾病的变化,给予合理的治疗。.
引用
- Wang Z, Xu MZ, Chen YF, et al. [Therapy-related myeloid neoplasms after successful treatment for acute promyelocytic leukemia: a report of four cases and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 32023731. doi:10.3760/cma.j.issn.0253-2727.2019.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。